Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in AtriCure, Inc. (NASDAQ:ATRC)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 90,693 shares of the medical device company’s stock, valued at approximately $2,926,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of AtriCure at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ATRC. American Century Companies Inc. bought a new stake in shares of AtriCure in the 4th quarter valued at approximately $516,000. Sei Investments Co. lifted its stake in shares of AtriCure by 6.1% in the 4th quarter. Sei Investments Co. now owns 107,290 shares of the medical device company’s stock valued at $3,279,000 after purchasing an additional 6,152 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of AtriCure in the 4th quarter valued at approximately $321,000. LPL Financial LLC lifted its stake in shares of AtriCure by 5.4% in the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company’s stock valued at $350,000 after purchasing an additional 584 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of AtriCure by 43.1% in the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company’s stock valued at $11,160,000 after purchasing an additional 110,039 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ATRC has been the subject of several analyst reports. UBS Group lowered their price objective on AtriCure from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Wall Street Zen lowered AtriCure from a “buy” rating to a “hold” rating in a research note on Sunday, June 1st. JMP Securities reissued a “market outperform” rating and set a $60.00 price target on shares of AtriCure in a research note on Wednesday, April 30th. Finally, Needham & Company LLC decreased their price target on AtriCure from $51.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.67.

Insider Buying and Selling

In other AtriCure news, insider Vinayak Doraiswamy sold 2,500 shares of the firm’s stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total transaction of $83,600.00. Following the transaction, the insider directly owned 73,550 shares in the company, valued at $2,459,512. This trade represents a 3.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.50% of the stock is owned by insiders.

AtriCure Trading Down 4.5%

ATRC opened at $31.73 on Wednesday. The stock’s fifty day moving average is $32.25 and its two-hundred day moving average is $34.31. The company has a market capitalization of $1.57 billion, a P/E ratio of -39.17 and a beta of 1.56. AtriCure, Inc. has a 52 week low of $20.20 and a 52 week high of $43.11. The company has a quick ratio of 2.88, a current ratio of 4.11 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.13. The company had revenue of $136.14 million for the quarter, compared to the consensus estimate of $130.17 million. AtriCure had a negative return on equity of 5.68% and a negative net margin of 7.95%. AtriCure’s quarterly revenue was up 17.1% on a year-over-year basis. During the same period last year, the business posted ($0.17) EPS. Analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.